Cysteinyl leukotriene receptor antagonist (LTRA)
This page covers all Cysteinyl leukotriene receptor antagonist (LTRA) drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CysLT1 (cysteinyl leukotriene receptor 1), CysLT1 receptor.
Targets
CysLT1 (cysteinyl leukotriene receptor 1) · CysLT1 receptor
Marketed (5)
- Comparator: Montelukast · Organon and Co · Respiratory / Immunology
Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and immune cells, preventing leukotriene-mediated inflammation and bronchoconstriction. - Montelukast (drug) · Firestone Institute for Respiratory Health · Respiratory / Immunology
Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and immune cells, preventing leukotriene-mediated inflammation and bronchoconstriction. - montelukast (MON) · GlaxoSmithKline · Respiratory / Immunology
Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and immune cells, preventing leukotriene-mediated inflammation and bronchoconstriction. - MK0476; montelukast sodium · Organon and Co · Respiratory / Immunology
Montelukast sodium blocks cysteinyl leukotriene receptors (CysLT1) on airway and inflammatory cells, preventing leukotriene-mediated bronchoconstriction and inflammation. - montelukast (Singulair) · University of Bologna · Respiratory / Immunology
Montelukast blocks cysteinyl leukotriene receptors (CysLT1) on airway and immune cells, preventing leukotriene-mediated inflammation and bronchoconstriction.
Phase 3 pipeline (1)
- Comparator: pranlukast · Organon and Co · Respiratory / Immunology
Pranlukast is a cysteinyl leukotriene receptor antagonist that blocks the inflammatory effects of leukotrienes in the airways.
Patent intelligence
- cysteinyl leukotriene receptor antagonist patent landscape — aggregated cliff calendar, attackable patents, originator estates